Description: SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Home Page: www.sellaslifesciences.com
Times Square Tower
New York,
NY
10036
United States
Phone:
646 200 5278
Officers
| Name | Title |
|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, CEO & Director |
| Mr. John Thomas Burns CPA | Senior VP & CFO |
| Ms. Stacy E. Yeung | VP, Associate General Counsel & Head of Compliance |
| Dr. Dragan Cicic M.D., MBA | Senior Vice President of Clinical Development |
| Mr. Andrew Elnatan | VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.7349 |
| Price-to-Sales TTM: | 27.9815 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |